Self URI: This article is available from https://www.sapd.es/revista/2024/47/4/03/fulltext
Fecha de recepción: 15 Febrero 2024
Fecha de aceptación: 02 Mayo 2024
Fecha de publicación: 30 Agosto 2024
R Mendoza Rodríguez
Virgen de las Nieves Hospital. Granada.
MC Fernández Cano
A Carrero Castaño
E Redondo Cerezo
Diarrhoea is the cardinal symptom of multiple pathologies in the digestive system, with multiple aetiopathogenesis. Chronic causes include pathologies such as coeliac disease, the main cause of villous atrophy in the small intestine. However, diarrhoea can also appear as an adverse reaction to drugs, sometimes with a pathophysiological basis in non-celiac enteropathy, causing malabsorptive syndromes. Angiotensin II receptor antagonist antihypertensives, such as Olmesartan, used to treat hypertension, diabetic nephropathy and heart failure, can cause enteropathy. Although rare, this condition should be considered in patients with severe diarrhoea and weight loss. The exact pathophysiology is unknown, but a type I immune response and inhibition of TGF-β, a key molecule in intestinal homeostasis, are suspected.
Olmesartan enteropathy occurs in both sexes, mainly in the elderly, and is characterised by chronic diarrhoea, weight loss and steatorrhoea. Laboratory abnormalities are variable, histological findings are non-specific and there is no response to a gluten-free diet. Clinical improvement after discontinuation of the drug confirms the diagnosis.
Treatment consists of discontinuation of Olmesartan, which usually results in complete resolution of symptoms. The prognosis is excellent, and follow-up endoscopy is not required if symptoms improve after withdrawal of the drug and there is no diagnostic uncertainty with another entity.
Keywords: olmesartan, enteropathy, diarrhoea.
Tanto si ha olvidado su contraseña, como si se ha bloqueado por intentos erróneos de conexión deberá:solicitar nueva contraseña